Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases

CONCLUSIONS: Our findings indicate that NMV-r to treat COVID-19 could reduce all-cause hospitalization and death in patients with CVDs.PMID:37965890 | DOI:10.1080/14787210.2023.2284367

Source: Expert Review of Anti-Infective Therapy - November 15, 2023 Category: Infectious Diseases Authors: Ting-Hui Liu Jheng-Yan Wu Po-Yu Huang Wan-Hsuan Hsu Min-Hsiang Chuang Ya-Wen Tsai Chih-Cheng Lai Chun-Yen Huang Source Type: research